Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hodgkin's disease

M M Hudson1, S S Donaldson

  • 1Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Pediatric Clinics of North America
|August 1, 1997
PubMed
Summary
This summary is machine-generated.

Pediatric Hodgkin's disease survival is high, with evolving treatments reducing long-term side effects. Risk-adapted therapies maintain cure rates for early stages, but further research is needed for high-risk patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicting the 10-year risk of cardiomyopathy in long-term survivors of childhood cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

The role of physical activity, sedentary behaviour, diet, adiposity and body composition on health-related quality of life and cancer-related fatigue after diagnosis of colorectal cancer: a Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis.

ESMO open·2025
Same author

The chance of transition: strategies for multidisciplinary collaboration.

Endocrine connections·2022
Same author

Stable transformation and regeneration of transgenic plants of Pinus radiata D. Don.

Plant cell reports·2019
Same author

The Impact of Persistent Leukoencephalopathy on Brain White Matter Microstructure in Long-Term Survivors of Acute Lymphoblastic Leukemia Treated with Chemotherapy Only.

AJNR. American journal of neuroradiology·2018
Same author

The influence of genetic variation on late toxicities in childhood cancer survivors: A review.

Critical reviews in oncology/hematology·2018
Same journal

Barriers, Breakthroughs, and the Future of Pediatric Dermatologic Care.

Pediatric clinics of North America·2026
Same journal

Advancing Pediatric Dermatology: Innovations in Care and Access.

Pediatric clinics of North America·2026
Same journal

No Child Left Behind: Advancing Access in Pediatric Dermatology, a 4-Year, Single-Center Experience.

Pediatric clinics of North America·2026
Same journal

Telemedicine and Access to Pediatric Dermatology Care.

Pediatric clinics of North America·2026
Same journal

Inequitable Reimbursement for Pediatric Providers: A Review of Structural Factors that Disincentivize the Care of Children.

Pediatric clinics of North America·2026
Same journal

Medical Photography's Power to Change Medical Care.

Pediatric clinics of North America·2026
See all related articles

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Cancer Treatment Research

Background:

  • Hodgkin's disease etiology remains incompletely understood.
  • Pediatric Hodgkin's disease treatment has evolved to minimize late sequelae.
  • Most children and adolescents with Hodgkin's disease achieve long-term survival.

Purpose of the Study:

  • To review the evolution of staging and treatment for pediatric Hodgkin's disease.
  • To assess the impact of risk-adapted combined modality regimens.
  • To identify future challenges in optimizing therapy for high-risk patients.

Main Methods:

  • Clinical staging of pediatric Hodgkin's disease.
  • Multimodality treatment including chemotherapy and low-dose radiation therapy.

Related Experiment Videos

  • Implementation of risk-adapted regimens with limited chemotherapy and radiation.

    • Main Results:

    • Risk-adapted combined modality regimens maintain cure rates for early-stage, favorable Hodgkin's disease.
    • Current treatments aim to reduce late treatment-related side effects.
    • The majority of pediatric patients are long-term survivors.

    Conclusions:

    • Risk-adapted therapy shows promise in maintaining cure rates while reducing toxicity.
    • Further identification of prognostic factors is crucial for intensifying therapy in at-risk patients.
    • Continued research is needed to improve outcomes for all pediatric Hodgkin's disease patients.